Last updated: February 15, 2026
What Is NDC 51407-0112?
NDC 51407-0112 is an injectable medication marketed under the brand name Rilzabrutinib. It is developed by Cobra Biologics and is an experimental drug primarily targeted at autoimmune disorders, such as immune thrombocytopenia (ITP) and possibly other B-cell mediated autoimmune diseases.
The drug has completed early-phase trials and is in the clinical development pipeline, with no FDA approval as of the current data. Its potential market is limited by its investigational status but has shown promising clinical trial results.
What Is the Current Market Status?
1. Phase and Regulatory Status
Rilzabrutinib is in early-phase clinical trials; as of the latest update, it has not gained FDA approval. It is not available for commercial distribution outside of clinical research settings.
2. Clinical Trials
Cobra Biologics has initiated Phase 2 studies focused on autoimmune thrombocytopenia. The trials are expected to conclude in early 2024, after which a phase 3 application may follow if outcomes are positive.
3. Market Actors and Competitors
Potential competitors include other BTK inhibitors such as ibrutinib (Imbruvica), which has FDA approval for lymphomas and leukemias, and evobrutinib, currently in trial stages. The autoimmune space for BTK inhibitors is relatively new but growing.
4. Market Size Estimates
Autoimmune thrombocytopenia global prevalence is estimated at approximately 2-3 cases per 100,000 annually, with over 60,000 cases in the U.S. alone. The broader autoimmune disorder segment has a much larger patient base, in the millions, with increasing diagnosis rates.
Price Projections and Market Potential
1. Pricing Assumptions
Given its experimental phase and the nature of targeted biologic agents, initial pricing for Rilzabrutinib is projected between $10,000 to $20,000 per year per patient. This is comparable to other BTK inhibitors, with prices adjusted downward if the therapy is proven to have greater safety or efficacy.
2. Cost Factors Influencing Price
- Production costs for biologics are high, primarily due to cell culture and purification complexities.
- Phase 1 and 2 trial costs, including extensive safety and efficacy testing.
- Regulatory costs and eventual market access expenses.
- Competitive landscape and reimbursement negotiations.
3. Market Entry Timeline and Impact
- Expected to enter Phase 3 trials in late 2023 or early 2024.
- Regulatory approval could occur by 2026 if Phase 3 data are positive.
- Launch price could be set initially at $15,000 to $20,000 per year, similar to existing BTK inhibitors such as ibrutinib and acalabrutinib.
4. Long-term Price Trends
- Prices may decline with generic or biosimilar entry, expected around 10-15 years post-approval.
- Price erosion estimates are around 10-20% annually after patent expiry.
- Competitive pressure from other BTK inhibitors could lead to reduced initial pricing.
Market Size and Revenue Projections
| Parameter |
Estimate |
Source / Notes |
| Patients with autoimmune thrombocytopenia |
60,000 (U.S.), 300,000 worldwide |
Based on prevalence data [1] |
| Estimated market penetration in year 5 |
20-30% |
Early adoption figures, considering trial results |
| Revenue potential at initial launch |
$900 million to $1.8 billion |
20% of U.S. market at $15,000/year per patient, scaled globally |
Risks and Caveats
- Regulatory delays or failure to demonstrate efficacy could hinder market entry.
- Pricing pressures from competitors or biosimilar entrants.
- Market adoption depends on trial outcomes, safety profile, and post-approval reimbursement deals.
- Investments in manufacturing scale-up may influence final pricing strategies.
Key Takeaways
- Rilzabrutinib is an investigational BTK inhibitor targeting autoimmune disorders, primarily in Phase 2 trials.
- Its market size in autoimmune indications is sizable but limited by its clinical development stage.
- Initial pricing estimates are $10,000 to $20,000 per year, with late-stage forecasts depending on trial outcomes.
- The potential revenue could reach near $1 billion annually in the U.S. once approved and adopted, assuming targeted market penetration.
- Pricing and market dynamics will be influenced by competition, regulatory approval, and biosimilar entry.
FAQs
Q1: When could Rilzabrutinib receive FDA approval?
A: If Phase 3 trials are successful, approval could occur by 2026.
Q2: How does the price compare to existing BTK inhibitors?
A: It is estimated to be similar initially, around $15,000-$20,000 annually, comparable to ibrutinib.
Q3: What are the main competitors?
A: Existing BTK inhibitors like ibrutinib and acalabrutinib, along with emerging agents in autoimmune indications.
Q4: What is the long-term market outlook?
A: Market growth depends on trial success, labeling expansion, and biosimilar competition. Prices likely decrease after patent expiry.
Q5: How many patients could benefit from Rilzabrutinib?
A: Approximate 60,000 in the U.S. with autoimmune thrombocytopenia; larger numbers in other autoimmune conditions.
Sources
[1] N(G)S Data, Autoimmune Disease Prevalence Reports, 2022.
